Lilly shares slide amid Trulicity, Taltz pricing concerns

Shares of Eli Lilly slid Wednesday after the company reported weaker-than-expected 3Q19 sales for drugs affected by high rebates and discounts.

Eli Lilly and Co. (NYSE:LLY) lost $2.4 billion in market cap, closing the day down $2.44

Read the full 371 word article

User Sign In